Refereed Publications 1996-2011 (excludes meeting abstracts)
1969
Fern EB, Hider RC and London DR. The sites of hydrolysis of
dipeptides containing leucine and glycine by rat jejunum invitro.
Biochem. J., 114, 885-861.
1969
Hider RC, Fern EB and London DR. Relationship between
intracellular aminoacids and protein synthesis digitorum longus
muscle of rats. Biochem. J., 144, 171-178.
1970
Loehry CA, Axon AT, Hilton PJ, Hider RC and Creamer B.
Permeability of the small intestine to substances of different
molecular weight. J. Brit. Soc. Gastroenterology, 11, 446-470.
1971
Fern EB, Hider RC and London DR. Studies invitro of free amino acid
pools and protein synthesis in rat jejunum. Europ. J. Clin. Invest., 1,
211-215.
1971
Hider RC, Fern EB and London DR. Identification in skeletal muscle
of a distinct extracellular pool of amino acids, and its role in protein
synthesis. Biochem J., 121, 817-827.
1971
Hider RC, Fern EB and London DR. The effect of insulin on free acid
pools and protein synthesis in rat skeletal muscle invitro. Biochem J.,
125, 751-756.
1972
Hider RC and John DI. Synthesis of trans-4, 5-didehydro-DL-lysine
(2,6-diamino-hex-4-enoic
acid)
and
of
4-oxo-L-lysine
(2,6-diamino-4-oxohexanoic acid). J. Chem. Soc. (Perkin I), 1825 –
1830.
1972
Hider RC and Meade L. The conversion of [1-14C] pyruvate into [14C]
alanine in rat skeletal muscle: Its relevance to the effect of insulin on
protein synthesis. Biochem. J., 128, 165-167.
1973
Clarke S, Hider RC and John DI. N-Phthaloylation of chloro- and
hydroxy-2-amino acids. J. Chem. Soc. (Perkin I), 230-234.
1973
Hider RC and John DI. Biosynthesis of lathyrine in Lathyrus
tingitanus. Photochemistry, 12, 119-124.
1974
Bunce AS and Hider RC. The composition of black lipid membranes
formed from egg-yolk lecithin, cholesterol and n-decane. Biochimica
Biophysica Acta., 363, 423-427.
1977
Drake AF, Dufton MJ, and Hider RC. The flexible nature of a critical
peptide region common to all Elapidae “short” neurotoxins. FEBS
Letts., 83, 202-206.
1977
Dufton MJ and Hider RC. Snake toxin secondary structure
predictions – structure activity relationships. J. Mol. Biol., 115,
177-193.
1977
Fellows LE, Hider RC and Bell EA. 3-[2-Amino-2-imidazolin-4(5)-yl]
alanine (Enduracididine) and 2-[2-amino-2-imidazolin-4(5)-yl] acetic
acid in seeds of lonchocarpus sericeus. Phytochemistry., 16, 1957-1959.
1978
Ash PS, Bunce AS, Dawson CR and Hider RC. The effect of synthetic
polymers on the electrical and permeability properties of lipid
membranes. Biochim. Biophys. Acta., 510, 216-229.
1978
Dawson CR, Drake AF, Helliwell J and Hider RC. The interaction of
bee melittin with lipid bilayer membranes. Biochim. Biophys. Acta.,
510, 75-86.
1978
Hider RC, Lloyd JC and Wheeler P. The application of 125I-labelled
copolymers of vinyl-pyrrolidone and acrylic acid for permeability
measurements of biological membranes. J. Colloid and Interface
Science., 65, 1-8.
1979
Drake AF and Hider RC. The structure of melittin in lipid bilayers.
Biochim. Biophys. Acta., 555, 371-373.
1979
Hider RC. An alternative view of the structure of the reactive site in
the short series snake venom postsynaptic neurotoxins. Adv.
Pharmacol., 3, 149.
1979
Hider RC, Neilands J and Silver J. Identification of iron(II)
enterobactin and its possible role in E. coli iron transport. FEBS
Letts., 102, 325-328.
1979
Hider RC. The structure of the reactive site in Elapidae neurotoxins.
Toxicon., 17, 70.
1980
Drake AF, Dufton MJ and Hider RC. The circular dischroism of
Elapidae snake toxins. Eur. J. Biochem., 105, 623-630.
1980
Dufton MJ and Hider RC. Lethal protein conformations. Trends in
Biochem Sci., 56-53.
1980
Hider RC. A proposal for the structure of conotoxin – a potent
antagonist for the nicotine acetylcholine receptor. FEBS Letts., 184,
181-184.
1980
Hider RC and Dufton MJ. The structure of the reactive site in
Elapidae neurotoxins. Natural Toxins (eds. Eaker and Wadstrom),
515-522.
1980
Hider RC and McCormack WJ. Facilitated amino acid transport
across organic phases and erythrocyte membranes. Biochem J., 188,
541-548.
1980
Hider RC and Ragnarsson U. A proposal for the structure of apamin.
FEBS Letts., 111, 189-193.
1980
Hider RC, Drake AF, Kuroda R and Neilands JB. Symport transport of
ferrichrome-type siderophores. Naturwissenschaften., 67, 136-139.
1981
Ash PS, Hider RC, Menez A and Wunderer G. Surface activity of
polypeptide toxins isolated from Anemonia sulcata. Biochim. Biophys.
Acta., 667, 197-208.
1981
Hider RC and Ragnarsson U. A comparative structural study of
apamin and related bee venom peptides. Biochim. Biophys. Acta.,
667, 197-208.
1981
Hider RC and Ragnarssson U. Secondary structure predictions on
apamin and some related bee venom components. Proceedings of the
16th European Peptide Symposium, (ed. K Brunfeldt), 666-671.
1981
Hider RC, Mohd-Nor R, Silver J, Morrison I and Rees L. Model
compounds for microbial iron-transport compounds. Part I. Solution
chemistry and Mossbauer study of iron(II) and iron(III) complexes
from phenolic and catecholic systems. J. Chem. Soc, (Dalton),
609-622.
1981
Hider RC, Smart LS and Suleiman M. The effect of harmaline and
harmala alkaloids on ouabain stimulated contractions of the
guinea-pig ileum. Eur. J. Pharmacology, 71, 83-92.
1981
Hider RC, Smart LS and Suleiman M. The effect of harmaline and
related B-carbolines on the acetylcholine stimulated contractions of
guinea-pig ileum. Eur. J. Pharmacology, 70, 429-436.
1982
Barber M, Bordoli R, Sedgwick RD, Tyler AN and Hider RC. Fast atom
bombardment mass spectroscopy (FAB-MS) of the large
oligopeptides, melittin, glucagon and chain of bovine insulin.
Biomedical Mass Spect, 9, 265-268.
1982
Bouet F, Menez A, Hider RC and Fromageot P. Separation of
intermediates in the refolding of reduced erabutoxin b by analytical
isoelectric focusing in layers of polyacrylamide gel. Biochem. J., 201,
495-499.
1982
Dell A, Hider RC, Barber M, Bordoli RS and Neilands JB. Field
desorption and fast atom bombardment mass spectrometry of
hydroxamate containing siderophores. Biomed. Mass Spect, 9,
158-161.
1982
Hamed MY, Hider RC and Silver J. The competition between
enterobactin and glutathione for iron. Inorganica Chimica. Acta
(Bioinorganic Section), 66, 13-18.
1982
Hider RC and Harvey AL. The structure and actions of cardiotoxins.
South African J. Science, 78, 350-356.
1982
Hider RC and Khader F. Biochemical and pharmacological properties
of cardiotoxins isolated from cobra venom. Toxicon, 20, 175-179.
1982
Hider RC, Drake AF, Inagaki F, Williams RJP, Endo T and Miyatawa T.
The molecular conformation of α-cobratoxin as studied by nuclear
magnetic resonance and circular dichroism. J. Mol. Biol, 158,
275-291.
1982
Hider RC, Mohd-Nor R, Silver J and neilands JB. The coordination of
calcium by iron enterobactin. J. Inorganic Biochemistry, 17, 205-213.
1982
Hider RC, Silver J and Howlin B. Model compounds for microbial
iron-transport compounds (Part 3). Solution chemistry and
Mossbauer study of iron(II) and iron(III) compounds from
2,3-dihydroxypyridine and 2-mercapto-3-pyridinol. J. Chem. Soc.
(Dalton), 1433-1438.
1983
Douglas KT, Sharma RK, Warmsley JF and Hider RC. Ionisation
process of some harmala alkaloids. Mole. Pharmacol, 23, 614-619.
1983
Dufton MJ and Hider RC. Classification of phospholipase-A2
according to sequence. Eur. J. Biochem, 137, 545-551.
1983
Dufton MJ and Hider RC. Conformational properties of the
neurotoxins and cytotoxins isolated from elapid snake venoms.
C.R.C. Critical Reviews in Biochemistry, 14, 113-171.
1983
Dufton MJ, Eaker D and Hider RC. Conformational properties of
phospholipase-A2. Eur. J. Biochem, 137, 537-544.
1983
Harvey AL, Hider RC and Khader F. The effects of phospholipase-A2
on actions of cobra venom cardiotoxins on erythrocytes and skeletal
muscle. Biochim. Biophys. Acta, 728, 215-221.
1983
Hider RC, Khader F and Tatham AS. Lytic activity of monomeric and
oligomeric melittin. Biochim. Biophys. Acta, 728, 222-229.
1983
Tahir S and Hider RC. An affinity ligand for phospholipase-A2
purification. Anal. Biochem, 135, 332-334.
1983
Tatham AS, Drake A and Hider RC. The effect of counterions on
melittin aggregation. Biochem. J., 211, 683-686.
1984
Agabaji A and Hider RC. A comparison of eel electroplax and snake
venom acetylcholine esterase. Comp. Biochem. Physiol, 78c, 211-216.
1984
Dotimas EM, Hider RC, Ragnarsson U and Tatham AS. Purification
of Bee venom peptides. Peptides, Proceedings of 18th European Peptide
Symposium (ed. U Ragnarsson), 141-144.
1984
Dufton MJ, Hider RC and Cherry RJ. The influence of melittin on the
rotation of band 3 protein in the human erythrocyte membrane. Eur.
Biophys. J., 11, 17-24.
1984
Harvey AL, Hider RC, Hodges SJ and Joubert FJ. Structure-activity
studies of homologues of short chain neurotoxins from Elapid snake
venoms. Brit. J. Pharmacol., 82, 709-716.
1984
Hider RC and Hodges SJ. Protein secondary structure analysis and
prediction. Biochemical Education, 12, 11-18.
1984
Hider RC, Bickar D, Morrison IEG and Silver J. Siderophore
iron-release mechanisms. J. Amer. Chem. Soc., 106, 6983-6987.
1984
Hider RC. Siderophore mediated absorption of iron. Structure and
Bonding., 58, 25-87.
1985
Blake DR, Winyard P, Lunec J, Williams A, Cornish A and Hider RC.
Cerebral and Ocular Toxicity Induced by Desferrioxamine. Quart. J.
Med., 56, 345-355.
1985
Dotimas EM and Hider RC. Bee venom peptides. Toxicon, 23, 561.
1985
Evans SV, Fellows LE, Janzen DH, Chambers J and Hider RC.
Erythro-y-hydroxyhomo-L-arginine: an amino acid from seed of
Lonchocarpus costaricansis, and its preferential interaction with
borate. Phytochemistry, 24, 1289-1292.
1985
Hider RC. Common features in the reactive sites of elapidae
neurotoxins and conotoxin. Toxicon, 23, 574.
1985
Hider RC, Ragnarsson U and Zetterqvist O. The role of the phosphate
group for the structure of phosphopeptide products of adenosine
3’,5’-cyclic monophosphate-dependent protein kinase. Biochem. J.,
229, 485-489.
1985
Hider RC. Studies on conotoxin and α-bungarotoxin. Seikaguku (J.
Jap. Biochem. Soc.), 27, 705-706.
1985
Inagaki F, Hider RC, Hodges SJ and Drake AF. Molecular
conformation of α- bungarotoxin as studied by nuclear magnetic
resonance and circular dichroism. J. Mol. Biol., 183, 575-590.
1985
Suleiman MS and Hider RC. The influence of harmaline on the
movements of sodium ions in smooth muscle of the guinea-pig ileum.
Mol. And Cell. Biochem., 67, 145-150.
1986
Freeman C, Hider RC and Catlow R. The conformation of apamin.
FEBS Letts., 21, 231-234.
1986
Gyparaki M, Hider RC, Huehns ER and Porter JB. Hydroxypyridinone
iron chelators: in vitro, and in vivo evaluation. Thalassaemia Today
(ed. Sirchia and Zanella), 289-296.
1986
Hider RC. The Facilitation of Iron Uptake in Bacteria and Plants by
substituted Catechols. Iron Siderophores and Plant Diseases, (ed. TR
Swinburne), 38-45.
1986
Hider RC, Walkinshaw MD and Saenger W. Erythrina Alkaloid
Nicotinic Antagonists: Structure-activity Relationships. Eur. J. Med.
Biochem., 21, 231-234.
1987
Barrand MA, Callingham BA and Hider RC. Effects of the Pyrones,
Maltol and Ethylmaltol, on Iron Absorption from the Rat Small
Intestine. Brit. J. Pharmacol., 39, 203-211.
1987
Hider RC. Characteristics of Iron(III) uptake by isolated fragments
of rat small intestine in the presence of the hydroxypyrones, maltol
and ethylmaltol. Biochem. Pharmacol., 37, 2051-2057.
1987
Dotimas E, Hameed K, Hider RC and Ragnarsson U. Isolation and
Structure Analysis of Bee Venom Mast Cell Degranulating Peptide.
Biochim. Biophys. Acta., 911, 285-293.
1987
Dotimas EM, Hameed K, Hider RC and Ragnarsson U. Honey Bee
Venom. Bee World, 68, 51-70.
1987
Drake A and Hider RC. The origin of the 225-230 nm circular
dichroism band in proteins. Biopolymers, 22, 113-118.
1987
Gyparaki M, Hider RC, Hirani S, Streater M, Huehns ER and Porter JB.
Hydroxypyridone iron chelators: in vitro and in vivo evaluation.
Acta. Haematol., 73, 44-49.
1987
Hajjawi OS and Hider RC. Malonate transport in human red blood
cells. Mol. And Cell. Biochem., 75, 43-49.
1987
Hider RC, Drake AF, Morrison IEG, Kupryszewski G and Wilusz T.
Structural analysis of trypsin inhibitors isolated from cucurbitacae
seeds: Circular dichroism studies. Int. J. peptide Protein Chem., 29,
397-403.
1987
Hodges S, Agbagi A, Harvey A and Hider RC. Cobra cardiotoxins:
Purification, effects on skeletal muscle, and structure-activity in
relationships. Eur. J. Biochem., 165, 373-383.
1988
Brady MC, Lilley KS, Treffry A, Harrison PM, Hider RC and Taylor
PD. Release of iron from ferritin molecules and their iron cores by
3-hydroxypyridinone chelators in vivo. J. Inorg. Biochem., 35, 9-22.
1988
Chiappinelli VA, Dryer SE, Sorenson DE and Hider RC, (Chiappinelli
ed.). Functional studies of neuronal nicotinic receptors utilizing
kappaneurotoxins. Nicotinic Acetylcholine Receptors in the Nervous
System, Springer Berlin, 15-29.
1988
Dufton MJ and Hider RC. Mode of action of cardiotoxins.
Encylcopaedia of Pharmacology and Therapeutics, 36, 1-40.
1988
Ford S, Cooper RA, Evans RW, Hider RC and Williams PH. Domain
preference in iron removal from human transferrin by the bacterial
siderophores aerobactin and enterochelin. Eur. J. Biochem., 178,
477-481.
1988
Grognet JM, Menez A, Drake AF, Morrison IEG and Hider RC.
Circular dichroism spectra of elapid cardiotoxins. Eur. J. Biochem.,
172, 383-388.
1988
Hider RC and Lerch K. The inhibition of tyrosinase by pyridinones.
Biochem. J., 175, 289-290.
1988
Hider RC, Drake AF and Tamiya N. An analysis of the 225-230 nm CD
band of elapid toxins. Biopolymers, 27, 113-122.
1988
Hider RC, Kupryszewski G, Rekowske P and Lammek B. Origin of the
positive 225-230 nm circular dichroism band in proteins: Its
application to conformational analysis. Biophys. Chem., 31, 45-51.
1988
Hider RC. Honeybee Venom: A rich source of pharmacologically
active peptides. Endeavour, 12, 60-65.
1988
Huehns ER, Porter JB and Hider RC. Selection of
hydroxypyridin-4-ones for the treatment of iron overload using in
vitro and in vivo models. Haemoglobin, 12, 593-600.
1988
Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V and
Hider RC. Iron mobilization from hepacyte monolayer cultures by
chelators: The importance of membrane permeability and iron
binding constant. Blood, 72, 1497-1505.
1988
Singh S and Hider RC. Colorimetric detection of the hydroxyl radical:
Comparison of the hydroxy-radical-generating ability of various
iron complexes. Anal. Biochem., 171, 47-54.
1988
Singh S and Hider RC, (Rice Evans and Halliwell eds.). A sensitive
method for detection of hydroxy radical production by various iron
complexes. Free Radicals: Methodology and Concepts, Richelieu Press,
London, 61-90.
1988
Smith DC and Hider RC. Thiol exchange catalysed refolding of small
proteins utilizing solid-phase supports. Biophys. Chem., 31, 21-28.
1988
Taylor PC, Morrison IEG and Hider RC. Microcomputer application
on non-linear regression analysis to metal-ligand equilibria. Talanta.,
35, 507-512.
1989
Hider RC. Absorption of ferric maltol, a novel ferric iron compound
in iron-defficient subjects. Clin. Lab. Haemat., 11, 287-290.
1989
Hewitt SD, Hider RC, Sarpong P, Morris CJ and Blake DR.
Investigations
of
the
anti-inflammatory
properties
of
hydroxypyridinones. Agents and Actions, 48, 382-388.
1989
Hider RC. Bijegif: Het venimn in de start. Natur and Techniek., 57,
422-433.
1989
Pall H, Blake DR, Winyard P, Lunec J, Williams A, Good PA, Kritzinger
EE, Cornish A and Hider RC. Ocular toxicity of desferrioxamine – an
example of copper promoted auto-oxidative damage? Brit. J.
Ophthalmology, 73, 42-47.
1989
Porter JB, Hoyes KP, Abeysinghe R, Huehns E and Hider RC. Animal
toxicology of iron chelator L1. Lancet, I, 156.
1989
Porter JB, Huehns ER and Hider RC. The development of iron
chelating drugs. Ballieres Clinical Haematology, (ed. C Hershco),
257-292.
1989
Sarti P, Antonini G, Malatesta F, Vallone B, Villaschi S, Brunori M,
Hider RC and Hammed K. Reconstitution of cytochrome-c-oxidase
into phospholipid vesicles stablised by hydrophobic polyvinyl
polymers. Biochem. J., 257, 783-787.
1989
Winyard PG, Hider RC, Brailsford S, Drake AF, Lunec J, and Blake DR.
Effects of oxidative stress on some physicochemical properties of
caeruloplasmin. Biochem. J., 258, 435-446.
1989
Winyard PG, Hider RC, Lunec J, Drake AF, Blake DR and Simic MG
(ed.). Role of oxidative modification on the lability of caeruloplasmin.
Oxygen Radicals in Biology and Medicine, Plenum Press, 341-345.
1990
Barrand MA, Hider RC and Callingham BA. The importance of
reductive mechanism for intestinal uptake of iron from ferric maltol
and ferric nitritriacetic acid (NTA). J. Pharm. Pharmacol., 42,
279-282.
1990
Dobbin PS and Hider RC. Iron chelation therapy. Chem. Britain, 26,
565-568.
1990
Epemolu RO, Singh S, Hider RC and Damani LA. Metabolism and
pharmacokinetics of novel orally active hydroxypyridinone iron
chelators in rats. Human Experimental Toxicol., 9, 332-337.
1990
Hall AD, Hider RC and Greene RJ. The interaction of orally
administered iron with levodopa and methyldopa therapy. J. Pharm.
Pharmacol., 42, 502-504.
1990
Hershko C, Link G, Pinson A, Avramovici-Grisaru S, Sarel S, Peter HH,
Hider RC and Grady RW. New orally effective iron chelators. Annals
New York Acad. Sci., 351-360.
1990
Hider RC. Absorption of ferric maltol, a novel ferric iron compound,
in iron-deficient subjects. Clin. And Lab. Haematol., 11, 287-290.
1990
Hider RC, Ejim L, Taylor PD, Gale R, Huehns ER and Porter JB.
Facilitated uptake of zinc into human erythrocytes. Biochem.
Pharmacol., 39, 1005-1012.
1990
Hider RC. Il veleno delle api:una riserva di formaci peril futuro.
Scienza and Technica, 231-236.
1990
Hider RC, Taylor PD, Walkinshaw M, Wang JL and van der Helm D.
The
interaction
between
iron(III)
and
1,2-dimethyl-3-hydroxypyridin-4-one. Chem. Res., 316-317.
1990
Perkins TDJ, Hider RC, Barlow DJ. Proposed solution structure of
endothelin. Int. J. Pept. Prot. Res., 36, 128-133.
1990
Porter JB, Hider RC and Huehns ER. Update on the
hydroxypyridinone oral iron-chelating agents. Seminars in Haematol.,
27, 25-100.
1990
Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER and Hider RC.
Relative oral efficacy and acute toxicity of hydroxypyridin-4-one
iron chelators in mice. Blood, 76, 2389-2396.
1990
Singh S, Hider RC and Porter JB. A direct method for quantification
of non-transferrin bound iron. Anal. Biochem., 186, 320-323.
1990
Singh S, Hider RC and Porter JB. Separation and identification of
desferrioxamine and its iron chelating metabolites by high
performance liquid chromatography and fast atom bombardment
mass spectrometry: Choice of a complexing agent and application to
biological fluids. Anal. Biochem., 187, 212-219.
1990
Streater M, Taylor PD, Hider RC and Porter JB. Novel
3-hydroxy-2(IH)-pyrididones.
Synthesis,
iron(III)
chelating
properties and biological activity. J. Med. Chem., 33, 1749-1755.
1991
Assadullahi T, Hider RC and McAuley AJ. Liposome formation from
synthetic poyhydroxyl lipids. Biochim. Biophys. Acta., 1083, 271-276.
1991
Barrand MA, Callingham BA, Dobbin PS and Hider RC. Dissociation of
a ferric maltol complex and its subsequent metabolism during
absorption across the small intestine of the rat. Brit. J. Pharmacol.,
102, 723-729.
1991
Hershko C, Link G, Peter HH, Dobbin PS and Hider RC. Iron
mobilization from mycocardial cells in 3-hydroxypyridin-4-one
chelators: studies in rat heart cells in culture. Blood, 77, 2049-2053.
1991
Hershko C, Theanacho EN, Spira DT, Peter HH, Dobbin PS and Hider
RC. The effect of N-alkyl modification on the antimalarial activity of
3-hydroxypyridin-4-one oral iron chelators. Blood, 77, 637-643.
1991
Hider RC and Dufton MJ. The structure and pharmacology of elapid
cytotoxins. The International Encyclopaedia of Pharmacology and
Therapeutics: Snake Venoms, Chapter 7, (ed. A Harvey), 259-302.
1991
Hider RC and Hall AD. Clinically useful chelators of tripositive
elements. Progr. Med. Chem., 28, 41-173.
1991
Hider RC and Hall AD. Iron chelating agents in medicine: the
application of bidentate hydroxypyridin-4-ones. Perspectives in
Bionorganic Chemistry, (ed. RW Hay), 209-253.
1991
Hider RC. Protein folding, Polypeptide and Protein Drugs –
Production, Characterisation and Formulation. Ellis Horwood, 31-53.
1991
Kelsey SM, Hider RC, Bloor JR, Blake DR, Gutteridge CN and Newland
AC. Absorption of low and therapeutic doses of ferric maltol, a novel
ferric iron compound in iron deficient subjects using a single dose
iron absorption test. J. Clin. Pharm. Therap., 16, 117-122.
1991
Porter JB, Hoyes KP, Albi E, Brooks PN, Huehns ER and Hider RC. The
subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron
chelators in overloaded and non-overloaded mice. Blood, 77, 700-720.
1991
Porter JB, Huehns ER and Hider RC. Hydroxypyridinones as Clinical
Iron Chelators. Blood, 78, 536.
1991
Stefani S, Chiancone E, Cavallo S, Saez V, Hall AD and Hider RC. The
interaction of hydroxypyridinones with human serum transferrin
and ovotransferrin. J. Inorganic. Biochem., 44, 27-37.
1992
Assadullahi T, Hamid K and Hider RC. In vitro stability of liposomes
in the presence of polymers, trehalose and sodium taurocholate. J.
Microencapsulation, 9, 317-327.
1992
Epemolu RO, Singh S, Hider RC and Damani LA. High-performance
liquid
chromatographic
determination
of
1,2-diethyl-3-hydroxypyridin-4-one and its 2-(hydroxyethyl)
metabolite in rat blood. J. Chromat. (Biomed. Appl.), 573, 178-182.
1992
Epemolu RO, Singh S, Hider RC and Damani LA. The
pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in
rats. Drug Metabolism and Disposition, 20, 736-741.
1992
Hershko C, Gordeuk VR, Thuma PE, Theanacho EN, Spira DT, Hider
RC, Peto TEA and Brittenham G. The antimalarial effect of iron
chelators: studies in animal models and in humans with mild
falciparum malaria. J. Inorg. Chem., 47, 267-277.
1992
Hider RC, Singh S and Porter JB. Iron Chelators in medicine and
biology. Proc. Roy. Soc. Edin., 99B, 137-168.
1992
Hoyes KP, Hider RC and Porter JB. Cell cycle synchronization and
growth inhibition by 3-hydroxypyridin-4-one iron chelators in
leukemia cell lines. Cancer Res., 52, 4591-4599.
1992
Namiranian S and Hider RC. Use of HPLC to demonstrate variation
of venom toxin composition in the Thailand cobra venoms Naja naja
kaouthia and Naja naja siamensis. Toxicon, 30, 47-67.
1992
Pattanapanyasat K, Webster HK, Tongtawe P, Kongcharoen P and Hider
RC. Effect of orally active hydroxypyridinone iron chelators on
human lymphocyte function. Brit. J. Haematol., 82, 13-19.
1992
Singh S and Hider RC. Iron chelating agents in chemistry of iron.
Chemistry of Iron (ed. J Silver), Blackie Publishing Group, Glasgow,
275-299.
1992
Singh S, Epemolu RO, Dobbin PS, Ellis BL, Damani LA and Hider RC.
Urinary metabolic profile in human and rat of 1,2-dimethyl and
1,2-diethyl substituted 3-hydroxypyridin-4-ones. Drug Metabolism
and Disposition, 20, 256-261.
1992
Singh S, Mohammed N, Ackerman RA, Porter JB and Hider RC.
Quantification of desferrioxamine and its iron chelating metabolites
by high performance liquid chromatography and simultaneous
UV-VIS/radioactive detection. Anal. Biochem., 203, 116-120.
1992
Xiao G, van der Helm D, Hider RC and Dobbin PS. Structure-stability
relationships of 3-hydroxypyridin-4-one complexes. J. Chem. Soc.
(Dalton), 3265-3271.
1992
Yesilada A, Theobald AE and Hider RC. Discrimination of bovine and
porcine insulin by higher-order derivative UV-spectroscopy. J.
Pharmaceut. Biomed. Anal., 10, 699-703.
1992
Zevin S, Link G, Grady RW, Hider RC, Peter HH and Hershko C.
Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one
iron chelators: studies in hypertransfused rats by selective radioiron
probes of reticuloendothelial and hepatocellular iron stores. Blood,
79, 248-253.
1993
Dean TP and Hider RC. Incorporation of alphaxalone into different
types of liposomes. J. Pharm. Pharmacol., 45, 900-922.
1993
Dobbin PS, Hider RC, Hall AD, Taylor PD, Sarpong P, Porter JB, Xiao
G and van der Helm D. Synthesis, physicochemical properties, and
biological
evaluation
of
N-substituted
2-alkyl-3-hydroxy-4(1H)-pyridinones:orally active iron chelators
with clinical potential. J. Med. Chem., 36, 2448-2458.
1993
Dobbin PS, Hider RC, Rizvi SK, Maki KL and van der Helm D. Study
of
hydrogen
bonding
in
1-ethyl-2-methyl-4-oxo-1,4-dihydropyridin-3-yloxyethanoic acid and
3-(1,2-diethyl-4-oxo-1,4-dihydropyridin-3-yloxy) propanoic acid by
1H NMR spectroscopy and x-ray crystallography. J. Chem. Soc.
Perkin, 2, 451-455.
1993
Dobbin PS, Hider RC, Ventatramani L, Siripitayananon J and van der
Helm
D.
Synthesis
and
structure
of
the
N-alkyl-2,6-dimethyl-4-oxopyridine-3-carboxylic acids. J. Heter.
Chem., 30, 723-737.
1993
Fredenburg AM, Wedlund PJ, Skinner TL, Damani LA, Hider RC and
Yokel
RA.
Pharmacokinetics
of
representative
3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. Drug
Metabolism and Disposition, 21, 256-258.
1993
Gower JD, Ambrose J, Manek S, Bright JR, Dobbin PS, Hider RC,
Goddard JD, Thorniley MS and Green CJ. The effect of synthetic
hexadentate iron chelator (CP130) and desferrioxamine on rabbit
kidneys exposed to cold and warm ischaemia. Agents and Actions, 40,
96-105.
1993
Hider RC. Development of oral iron chelators. Thailand Medical
Times, June, 17-22.
1993
Hider RC, Porter JB and Singh S. The design of therapeutically useful
iron chelators. The Development of Iron Chelators for Clinical Use. (ed.
Bergeron RJ and Brittenham GM), CRC Press, 353-371.
1993
Hoyes KP, Jones HM, Abeysinghe RD, Hider RC and Porter JB. In vivo
and in vitro effects of 3-hydroxypyridin-4-one chelators on murine
hemopoiesis. Experimental Hematology, 21, 86-92.
1993
Hoyes KP, Porter JB and Hider RC. Subcellular distribution of
desferrioxamine and hydroxypyridin-4-one chelators in K562 cells
affects chelation of intracellular iron pools. Brit. J. Haematol., 85,
393-400.
1993
Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB
and Singh S. Intravenous infusion pharmacokinetics of
desferrioxamine in thalassaemic patients. Drug Metabolism and
Disposition, 21, 640-644.
1993
Porter JB, Abeysinghe RD, Hoyes KP, Barra C, Huehns ER, Brroks PN,
Blackwell MP, Araneta M, Brittenham G, Singh S, Dobbin PS and Hider
RC. Contrasting interspecies efficacy and toxicology of
1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing
metabolism of the iron chelating site. Brit. J. Haematol., 85, 159-168.
1993
Singh S and Hider RC. Development of new clinical iron chelators in
Antioxidants, Free Radical and Polyunsaturated Fatty Acids. Biology
and Medicine, (ed. AT Diploche, JMC Gutteridge and VKS Shukla),
IFSC A/S.
1993
Walji F, Rosen A and Hider RC. The existence of conformationally
labile (preformed) drug binding sites in human serum albumin as
evidenced by optical rotation measurements. J. Pharm. Pharmacol.,
45, 551-558.
1993
Xiao G, van der Helm D, Goerlitz FH, Hider RC and Dobbin PS.
Structures of 3-hydroxy-1-(2-methoxy-ethyl)-2-methyl-4-pyridinone,
its hydrochloride and 1-ethyl-3-hydroxy-2- methyl-4-pyridinone
hydrochloride hydrate. Acta Cryst., C49, 1646-1649.
1993
Xiao G, van der Helm, Hider RC and Dobbin PS.
3-[1-(Ethylamino)ethylidene]-6-methyl-3H-pyran-2,4-dione.
Acta
Cryst., C49, 980-982.
1994
Abeysinghe RD, Ellis BL, Hider RC and Porter JB. Platelet labeling
with indium-hydroxypyridinone complexes. Eur. J. Nucl. Med., 21,
1141-1147.
1994
Carthew P, Smith AG, Hider RC, Darman D, Edwards RE and Francis
JE. Potentiation of iron accumulation in cardiac myocytes during the
treatment of iron overload with gerbils with the hydroxypyridinone
iron chelator CP94. Biometals, 7, 267-271.
1994
Chana SS and Hider RC. A novel macrobicyclic cryptand
incorporating endocyclic hydroxamate donor groups. Tetrahedron
Lett., 35, 9455-9458.
1994
Epemolu O, Ackerman R, Porter JB, Hider RC, Damani LA and Singh S.
HPLC determination of 1,2-diethyl-3-hydroxypyridinone, its iron
complex and glucuronide conjugate in serum and urine of
thalassaemia patients. J. Pharm. Biomed. Anal., 12, 923-930
1994
Hider RC, Epemolu O, Singh S and Porter JB. Iron chelator design.
Adv. Expt. Med & Biol., 356, 343-349.
1994
Hider RC, Porter JB and Singh S. The design of therapeutically useful
iron chelators in The Development of Iron chelators for Clinical Use
(Ed. RJ Bergeron & GM Brittenham), CRC Press, 353-371.
1994
Hider RC. The treatment of malaria with iron chelators. Exp. Opin.
Ther. Patents., 4, 931-940.
1994
Laidler P, Cowan DA, Hider RC and Kicman AT. New decision limits
and quality control material for detecting human chorionic
gonadotrophin misuse in sports. Clin. Chem., 40, 1306-1311.
1994
Maxton DG, Thompson RPH and Hider RC. Absorption of iron from
ferric hydroxypyranone complexes. Brit. J. Nutrition., 71, 203-207.
1994
Porter JB, Singh S, Hoyes KP, Epemolu O, Abeysinghe R and Hider RC.
Lessons
from
preclinical
and
clinical
studies
with
1,2-diethyl-3-hydroxypyridinone CP94, and related compounds. Adv.
Expt. Med. And Biol., 356, 361-370.
1994
Singh S and Hider RC. Therapeutic iron-chelating drugs. Free Radical
damage and its Control, (eds. CA Rice-Evans and RH Burdon) Elsevier
Science B.V., 28, 189-216.
1995
Xie X, Hider RC and Smart TG. Modulation of GABA-mediated
synaptic transmission by endogenous zinc in the immature rat
hippocampus in vitro. J. Physiol., 478, 75-86.
1995
Hider RC. Potential protection from toxicity by oral iron chelators.
Toxicology Letters, 82/83, 961-967.
1995
Laidler P, Cowan DA, Hider RC, Keane A and Kicman AT. Trytic
mapping of human chorionic gonadotrophin by matrix-assisted laser
desorption/ionization mass spectrometry. Rapid Comm. Mass Spec., 9,
1021-1026.
1995
Porter JB, Lynagh GR and Hider RC. Thymocyte apoptosis: a rapid
model for comparative screening of iron chelators. Implications for
treatment of iron overload in thalassaemia. Sickle cell disease and
thalassaemia: new trends in therapy (eds. Y Beuzard, B Lubin and J
Rosa) Colloque INSERM (J. Libbey Eurotext Ltd), 234, 371-372.
1995
Ward RJ, Dexter D, Florence A, Aouad F, Hider RC, Jenner P and
Crichton RP. Brain iron in the ferrocene-loaded rat: Its chelation and
influence on dopamine metabolism. Biochem. Pharmacol., 49,
1821-1826.
1995
Xiao G, van der Helm D, Hider RC and Dobbin PS. Crystal structure
and confirmational studies of the ferric hexadentate
N,N,N-Tris[2,(3-hydroxy-2-oxo-1,2-dihydropyridin-1-yl)acetamido]e
thylamine complex. Inorg. Chem., 34, 1268-1270.
1996
Abeysinghe RD, Roberts PJ, Cooper C, Hider RC and Porter JB. The
environment of lipoxygenase iron binding site explored with novel
hydroxypyridinone iron chelators. J. Biol. Chem., 271, 7965-7972.
1996
Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R and Porter
JB. The relationship of intracellular iron chelation to the inhibition
and regeneration of human ribonucleotide reductase. J. Biol.
Chem., 271, 20291-20299.
1996
Klair, S, Hider RC, Adams MZ, and Leigh RA. Studies of iron
transport in cereals using synthetic phytosiderophores. J. Plant.
Nutrit., 19, 1295-1307.
1996
Duhme AK, Dauter Z, Hider RC & Pohl S. Complexation of
molybdenum by siderophores: Synthesis and structure of the
double-helical cis-dioxomolybdenum (IV) complex of a
bis(catecholamide) siderophore analogue.
Inorg. Chem., 35,
3059-3061.
1996
Duhme AK, Hider RC & Khodr H. Spectrophotometric competition
study between molybdate and iron(III) hydroxide on
N,N-bis(2,3dihydroxybenzoyl)-L-lysine, a naturally occuring
siderophore synthesised by Azotobacter vinelandii. Biometals, 9,
245-248.
1996
Singh S, Choudhury R, Epemolu RO & Hider RC. Metabolism and
pharmacokinetics
of
1(2’-hydroxyethyl)and
1(3’-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat. Eur.
J.Drug Metabolism and Pharmacokinetics, 21, 33-41.
1996
Smith AG, Clothier B, Francis JE, Gibbs AH, DeMatteiu F & Hider RC.
Protoporphyria induced by orally active iron chelator
1,2-diethyl-3-hydroxypyrid-4-one in C57BL/10 ScSn mice. Blood,
89, 1045-1051.
1996
Porter JB, Abeysinghe RD, Singh S, Hider RC & Marshall L. Kinetics
of removal and reappearance of non transferrin bound plasma iron
with desferroxamine therapy. Blood, 88, 705-713.
1996
Ellis BL, Duhme AK, Hider RC, Hossain MB, Rizvi S & van der Helm
D.
Synthesis, physicochemical properties and biological
evaluation of hydroxypyranones and hydroxypyridinones: Novel
bidentate ligands for cell-labelling. J.Med.Chem. 39, 3659-3670.
1996
Kime R, Gibson, Hider RC and Powers H. A chromatographic method
for the determination of non-transferrin-bound iron (NTBI) suitable
for use on the plasma and bronchoalveolar lavage fluid from
preterm babies. Clinical Sciences, 91, 633-638.
1997
Smith AG, Clothier B, Francis JE, Gibbs AH, DeMatteiu F and Hider
RC. Protoporphyria induced by orally active iron chelator
1,2-diethyl-3-hydroxypyrid-4-one in C57BL/10 ScSn mice. Blood, 88,
1045-1051.
1997
Zanninelli G, Glickstein, H Breuer W, Milgram P, Brissot P, Hider RC,
Konijn AM, Libman J, Shanzer, A and Cabantchik ZI. Chelation and
mobilisation of cellular iron by different classes of chelators.
Molecular Pharmacology, 51, 842-852.
1997
Duhme AK, Hider RC and Khodr H. Synthesis and iron-binding
properties of Protochelin, the Tris(catecholamide) Siderophore of
Azotobacter vinelandii. Chem. Ber. 130, 969-973.
1997
Pattanapanyasat K, Thaithong S, Kyle DE, Udomsangpetch R,
Yongvanitchit K, Hider RC and Webster HK. Flow cytometric
assessment of hydroxypyridinone iron chelators on in vitro growth of
drug-resistant malaria. Cytometry 27, 84-91.
1998
Brown JE, Khodr H, Hider RC and Rice-Evans C. Structural
dependence of flavonoid interactions with Cu2+ ions: implications
for their antioxidant properties. Biochem. J. 330, 1173-1178.
1998
Duhme A-K, Hider RC, Naldrett MJ and Pau RN. The stability of the
molybdenum-axotochelin complex and its effect on siderophore
production in Azotobacter vinelandii. J. Bioinorg. Chem. 3, 520-526.
1998
Kayyali R, Pannala AS, Khodr H and Hider RC. Comparative
Radical Scavenging Ability of Bidentate Iron(III) Chelators.
Biochem. Pharmacol. 55, 1327-1332.
1998
Rai BL, Dekhordi LS, Khodr H, Jin Y, Liu Z-D and Hider RC.
Synthesis, physicochemical properties and evaluation of
N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. J. Med. Chem.
41, 3347-3359.
1998
Tilbrook GS and Hider RC. Iron Chelators for Clinical Use. Metal
Ions in Biological Systems Vol 35 (Ed A Sigel and H Sigel) Marcel
Dekker Inc, New York, pp 691-730.
1999
Bennett FA, Barlow DJ, Dodoo ANO, Hider RC, Lansley AB,
Lawrence MJ, Marriott C and Bansal S. Synthesis and properties of
(6,7-dimethoxy-4-coumaryl)alanine. A fluorescent peptide label.
Anal. Biochem. 270, 15-23.
1999
Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, and Hider RC.
Quantification of non-transferrin-bound iron in the presence of
unsaturated transferrin. Anal. Biochem. 273, 212-220.
1999
Habgood D, Liu Z-D, Dehkordi LS, Khodr H, Abbott J and Hider RC.
Investigation into the correlation between the structure of
hydroxypyridinones and blood-brain barrier permeability.
Biochem. Pharmacol. 57, 1305-1310.
1999
Hider RC, Bittel D, Andrews GK. Competition between
iron(III)-selective chelators and zinc-finger domains for zinc(II).
Biochem. Pharmacol. 57, 1031-1035.
1999
Liu DY, Liu Z-D, Lu SL and Hider RC. Gradient ion-pair
high-performance liquid chromatographic method for analysis of
3-hydroxypyridin-4-one iron chelators. J. Chromat. B. 730, 135-139.
1999
Liu Z-D, Liu DY, Lu SL and Hider RC. Synthesis, physicochemical
properties and biological evaluation of aromatic ester prodrugs of
1-(2’-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one
(CP102):
Orally active iron chelators with clinical potential. J. Pharm.
Pharmacol. 51, 1-12.
1999
Liu Z-D, Lu SL and Hider RC. In vivo iron mobilisation
evaluation of hydroxypyridinones in 59Fe-ferritin loaded rat
model. Biochem. Pharmacol. 57, 559-566.
1999
Rai BL, Liu ZD, Liu DY, Lu SL, Hider RC. Synthesis,
physicochemical properties and biological evaluation of ester
prodrugs of 3-hydroxypyridin-4-ones: design of orally active
chelators with clinical potential. Eur. J. Med. Chem. 34, 475-485.
1999
Rai BL, Khodr H and Hider RC. Synthesis, physiochemical and
iron(III)-chelating
properties
of
novel
hexadentate
3-hydroxy-2(1H)pyridinone ligands. Tetrahedron. 55, 1129-1142.
1999
Stalteri MA, Bansal S, Hider RC, Mather SJ. Comparison of the
stability of technetium-labeled peptides to challenge with cysteine.
Bioconjugate Chem. 10, 130-136.
1999
von Wirén N, Klair S, Bansal S, Briat J-F, Khodr H, Shioiri T, Leigh
RA and Hider RC. Nicotianamine chelates both FeIII and FeII.
Implications for metal transport in plants. Plant Physiol. 119,
1107-1114.
1999
Liu Z-D, Khodr H, Liu DY, Lu SL and Hider RC. Synthesis,
physiochemical characterisation and biological evaluation of
2–(1’–Hydroxyalkyl)–3–hydroxypyridin–4–ones:
Novel
Iron
3+
values.
J.Med.Chem. 42,
Chelators with Enhanced pFe
4814-4823.
1999
Ellis BL, Sampson CB, Abeysinghe RD, Porter JB, and Hider RC.
6-Alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for all
labelling with indium. Eur. J. Nucl. Med. Nul. 26, 1400-1406.
1999
Liu DY, Liu Z-D, Lu SL and Hider RC. Liquid extraction and
ion-pair
HPLC
for
determination
of
hydrophilic
3-hydroxypyridin-4-one iron chelators. J. Pharm. Biomed. Anal. 21,
789-765.
2000
Dodoo AN, Bansal S, Barlow DJ, Bennet FC, Hider RC, Lansley AB,
Lawrence MJ and Marriott C. Systematic Investigations of the
influence of molecular structure on the transport of peptides
across cultured alveolar cell monolayers. Pharm. Res. 17, 7-14.
2000
Liu Z-D, Khodr H, Lu SL and Hider RC. Design, synthesis and
evaluation of N-basic substituted. 3-hydroxypyridin-4-ones: Orally
active iron chelators with lysosomotrophic potential. J. Pharm.
Pharmacol. 52, 263-272.
2000
Loréal O, Gosriwatana I, Guyader D, Porter J, Brissot P, and Hider
RC. Determination of non-transferrin-bound iron in genetic
hemochromatosis using a new HPLC-based method. J. Hepatology.
32, 727-733.
2000
de Valk B, Addicks MA, Gosriwatana I, Lu S, Hider R.C & Marx JJM.
Non-transferrin-bound iron is present in plasma of subjects with
heterozygous hereditary haemochromatosis and normal plasma
iron saturation. Eur. J. Clin. Investigation. 30, 248-251.
2000
Hider RC, Liu Z-D & Piyamongkol. The design and properties of
3-hydroxpyridin-4-one iron chelators with high pFe(3+) values.
Transfusion Science, 23, 201-209.
2000
Lu S, Gosriwatana I, Liu D-Y, Liu Z-D, Mallet AI & Hider RC.
Biliary
and
unrinary
metabolic
profiles
of
1,2-diethyl-3-hydroxypyridin-4-one (CP94) in the rat. Drug Metab
Dispos, 28, 873-879
2000
Liu Z-D, Liu DY & Hider R.C. Design, synthesis, and biological
evaluation
of
aromatic
ester
prodrugs
of
1-(3'-Hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41) as
orally active iron chelators. Arzeim.-Forsch/Drug Res, 50, 461-470.
2000
Hider RC, Liu Z-D & Piyamongkol. The design and properties of
3-hydroxpyridin-4-one iron chelators with high pFe(3+) values.
Transfusion Science, 23, 201-209.
2000
Liu DY, Liu Z-D, Shu L, Hider RC. Hydrolytic and metabolic
characteristics
of
the
esters
of
(3'-Hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one
(CP41),
potentionally useful iron chelators. Pharmacology & Toxicology, 86,
228-233.
2000
Von Wiren N, Khodr H & Hider R.C. Hydroxylated
Phytosiderophore species possess an enhanced chelate stability and
affinity for iron(III). Plant Physiology, 124,1149-1157.
2001
Hider RC, Liu ZD, & Khodr HH. Metal Chelation of Polyphenols.
Methods in Enzymology, 335, 190-203.
2001
Liu ZD, Lockwood M, Rose S, Theobald, AE, & Hider RC.
Structure-activity
investigation
of
the
inhibition
of
3-hydroxypyridin-4-ones on mammalian tyrosine hydroxlase.
Biochemical Pharmacology, 61, 285-290.
2001
Liu ZD, Piyamongkol S, Lui DY, Khodr HH, Lu S, Hider RC.
Synthesis of 2-Amido-3-hydroxpyridin-4(1H)-ones: Novel Iron
Chelators with Enhanced pFe3+ Values. Bioorganic & Medicinal
Chemistry, 9, 563-573.
2001
Piyamongkol S, Liu ZD, Hider RC. Novel synthetic approach to
2-(1'-hydroxyalkyl)-and
2-amino-3-hydroxypyridin-4-ones.
Tetrahedron, 57, 3479-3486.
2001
Pattanapayasat K, Kotipun K, Yongvanitchit K, Hider RC, Kyle DE,
Heppner DG, Walsh DS. Effects of Hydroxypyridinone iron
chelators in combination with antimalarial drugs on the In vitro
growth of Plasmodium falciparum. Southeast Asia J. Trop. Med.
Public Health. Vol 32 p 64-69.
2001
Kayyali R, Porter JP, Liu ZD, Davies NA, Nugent JH, Cooper CE,
Hider RC. Structure-function investigation of the interaction of 1and 2- substituted 3-Hydroxypyridin-4-ones with 5-Lipoxygenase
and Ribonucleotide Reductase. J. Biol. Chem., 276, 86,
48814-48822.
2002
Liu ZD & Hider RC. Design of clinically useful Iron(III)-selective
chelators. Medicinal Research Reviews, 22, 26-64.
2002
Zanninelli G, Loreal O, Brissot P, Konijn M, Slotki IN, Hider RC &
Cabantchik ZI The labile iron pool of hepacytes in chronic and
acute iron overload and chelator iron deprivation. Journal of
Hepatology, 36, 29-46.
2002
Rooyakkers TM, Stroes ESG, Kooistra MP, van Fassen EF, Hider RC,
Rabelink TJ, Marx JJ. Ferric saccharate induces oxygen radical
stress and endothelial dysfunction in vitro. European Journal of
Clinical Investigation, 32, 9-16.
2002
Kooistra MP, Kerstring S, Goswriwatana I, Lu S, Nijhoff-Schutt J,
Hider RC & Marx JJM. Nontransferrin-bound iron in the plasma of
haemodialysis patients, after intravenous iron saccharate infusion.
European Journal of Clinical Investigation, 32, 36-41.
2002
Hider RC. Nature of nontransferrin-bound iron. European Journal
of Clinical Investigation, 32, 50-54.
2002
Georgiou NA, Van der Beuggen T, Oudshorn M, Hider RC, Marx JJ,
& von Asbeck BS. Human immunodeficiency virus type I
replication inhibition by the bidentate iron chelators CP502 &
CP511 is caused by proliferation inhibition and the onset of
apoptosis. European Journal of Clinical Investigation, 32, 91-98
2002
Moridani MY, Tilbrook GS, Khodr HH & Hider RC. Synthesis and
physicochemical
assessment
of
novel
2-substituted
3-hydroxpyridin-4-ones, novel iron chelators. Journal of Pharmacy
& Pharmacology, 54, 349-364.
2002
Liu ZD, Kayyali R, Hider RC, Porter JB & Theobald AE. Design,
synthesis
and
evaluation
of
novel
2-substituted
3-hydroxypyridin-4-ones. Structure-activity investigation of
metalloenzyme inhibition by iron chelators. J. Med. Chem., 45,
631-639.
2002
Liu ZD & Hider RC. Chapter 13, Iron Chelator Chemistry.
Molecular and Cellular Iron Transport, p321-357. Edited by DM
Templeton, Marcel Deaker Inc.
2002
Neubert H, Hider RC & Cowan DA. Speciation of Fe (III)-chelate
complexes by electrospray ionization ion and laser
desorption/ionization Fourier transform ion cyclotron resonance
mass spectrometry. Rapid Communications in Mass Spectrometry,
16, 1556-1561.
2002
Lui DY, Liu ZD, Piyamongkol S, Lu SL & Hider RC.
Characterisation of two isomeric b-D-glucosiduronic acids derived
from 1,2-dimethyl-3-hydroxypyridin-4-one (CP94) in rat liver
homogenate incubates. Journal of Pharmacy & Pharmacology, 54,
951-957.
2002
Loreal, O., Turlin, B., Pigeon, C, Moisan, A., Ropert, M., Morice, P.,
Gando, Y., Jouanolle, A., Verin, M., Hider, R.C., Yoshida, K., Brissot,
P. Aceruloplasminemia: new clinical, pathophysiological and
theapeutic insights. Journal of Hepatology, 36, 851-856.
2002
Lui, Z.D., Hider, R.C. Design of iron chelators with therapeutic
application. Coordination Chemistry Review, 232, 151-171.
2003
Hider, R.C., Liu, Z.D. Emerging understanding of the advantage of
small molecules such as hydroxypyridinones in the treatment of
iron overload. Current Medicinal Chemistry, 10, 1051-1064.
2004
Yongmin Ma, Wei Luo,, Peter J. Quinn, Zudong Liu, & Robert C.
Hider (2004)
Design, Synthesis, Physicochemical Properties, Chelators with
Fluorescent Sensors. J. Med. Chem, 47, 6349-6362
2004
Lewis EA, Khodr H, Hider RC, Lindsay Smith JR, Walton PH. (2004)
A manganese superoxide dismutase mimic based on cis,cis-1,3,
5-triaminocyclohexane. Dalton Transactions, (2), 187-188.
2004
Ren V, Houghton PJ, Hider RC & Howes MR. (2004)
Novel diterpenoid Acetylcholinesterase Inhibitors from Salvia
miltiorhiza. Planta medica, 70. 201-204
2004
Hider RC & Liu ZD (2004) Siderophores. Encyclopedia of
Supramolecular Chemistry, edited by Jerry L. Atwood and Jonathan
W. Steed, DOI: 10.1081/E-ESMC-120012714, Marcel Dekker
2004
Venkatasamy, Radhakrishnan; Faas, Laura; Young, Antony R.;
Raman, Amala; Hider, Robert C. Effects of piperine analogues on
stimulation of melanocyte proliferation and melanocyte
differentiation. Bioorganic & Molecular Chemistry, 12, 1905-1920
(2004)
2004
Luo W.; Ma Y.M.; Quinn P.J.; Hider R.C.; Liu Z.D. Design, synthesis
and properties of novel iron(III)-specific fluorescent probes.
Journal of Pharmacy and Pharmacology, 56, 529-536 (2004)
2004
Gaboriau F; Chantrel-Groussard K; Rakba N; Loyer P; Pasdeloup N;
Hider RC, Brissot P, & Lescoat G. Iron mobilization, cytoprotection,
and inhibition of cell proliferation in normal and transformed rat
hepatocyte cultures by the hydroxypyridinone CP411, compared
to CP20: a biological and physicochemical study.
Pharmacology, 67, 1479-1487 (2004)
Biochemical
2004
Tao Zhou, Robert C Hider, Zu D Lui & Hendrik Neubert. (2004)
Iron(III)-selective dendritic chelators. Tetrahedron Letters, 45,
9393-9396
2004
M. Merkofer, R. Kissner, R.C. Hider, W.H. Koppenol (2004) Redox
Properties of the Iron Complexes of CP20, CP502, CP 509 and
ICL670, Helv. Chim. Acta, 87, 3021-3034.
2004
Hider RC, Yoshimura E, Khodr H & von Wiren N. (2004)
Competition or complementation: the iron chelating abilities of
nicotianamine and phytosiderophores. New Phytologist, 164,
204-208.
2004
Hutchinson C, Al-Ashgar W, Liu DY, Hider RC, Powell JJ & Geissler
CA. (2004) Oral ferrous sulphate leads to a marked increase in
pro-oxidant non transferrin-bound iron. Eur. J. Clin. Invest, 34,
782-784.
2005
2005
2005
2005
2005
Piyamongkol S, Zhou T, Lui ZD Khodr H & Hider RC (2005)
Design and characterisation of novel hexadentate 3-hydroxypyridin-4-one
ligands.
Tetrahedron Letters, 46, 1133-1136
Ma Y, Luo W, Camplo M, Liu Z, Hider RC. (2005)
Novel iron-specific fluorescent probes
Bioorganic & Medicinal Chemistry Letters, 15, 3450-3452.
Piyamongkol S, Zhou T, Liu ZD, Khodr H & Hider RC. (2005)
Design and characterisation of novel hexadentate 3-hydroxypyridin-4-one
ligands
Tetrahedron Letters, 46, 1333-1336
Zhou T & Hider RC. (2005)
The Design of Orally Active Iron Chelators
N.Y. Acad. Sci., 1054, 1-14.
Shayeghi M, Latunde-Dada G, Oakhill JS, Laftah A, Takeuchi K, Halliday N, Khan
Y, Warley A, McCann F, Hider RC, Frazer DM, Anderson GJ, Vulpe CD, Simpson
RJ & McKie A. (2005)
Identification of an Intestinal Heme Transporter
Cell, 122, 1-13
2005
2005
2005
2005
2006
2006
2006
2006
2006
2006
Jacobs EMG, Handriks JCM, van Tits BLJH, Evans PJ, Breuer W, Liu DY, Jansen
EHJM, Jauhiainen K, Sturm B, Porter JB, Scheiber-Mojdehkar B, von Bonsdorff L,
Cabantchik ZI, Hider RC & Swinkels DW. (2005)
Results of an international round robin for the quantification of serum
non-transferrin-bound iron: Need for defining standardization and a clinically
relevant isoform.
Analytical Biochemistry, 341, 241-250.
Berndt UECh, Zhou T, Hider RC, Liu ZD & Neubert H. (2005)
Structural characterization of chelator-terminated dendrimers and their
synthetic intermediates by mass spectrometry
J. Mass Spectrom., 40, 1203-1214.
Zhou T, Liu ZD, Neubert H, Kong XL, Ma Y & Hider RC. (2005)
High affinity iron(III) scavenging by a novel hexadentate
3-hydroxypyridin-4-one-based dendrimer: Synthesis and characterization.
Bioorganic & Medicinal Chemistry Letters, 15, 5007-5011.
Gaeta, A & Hider, RC. (2005)
The crucial role of metal ions in neurodegeneration: the basis for a promising
therapeutic strategy
British Journal of Pharmacology, 146, 1041-1059
Merkofer, M, Domazou, A, Nauser, T & Koppenol, W.
Disassociation of CP20 from iron(II)(CP20)3: A pulse radiolysis study
Eur. J. Inorg. Chem. 671-675
Barrel, K, Balzarini, J, Neyts, J, de Clercq, E, Hider R C, & Camplo, M.
Synthesis and Antiviral Evaluation of Cyclic and Acyclic
2-Methyl-3-hydroxy-4-pyridinone Nucleoside Derivatives
J.Med. Chem. 49, 43-50
Kong, X, Zhou, T, Neubert, H, Liu, Z, & Hider, RC.
3-Hydroxy-2-(5-hydroxypentyl)-4H-chromen-4-one: A Bidentate or
Tridentate Iron(III) Ligand?
J. Med. Chem. 49, 3028-3031.
Yongmin, M, de Groot, H, Liu, Z, Hider, R C & Petrat, F.
Chelation and determination of labile iron in primary hepatocytes by
pyridinone fluorescent probes.
Biochem. J. 395, 49-55
Ma, Y, Luo, W, Camplo, M, Liu, Z, and Hider, RC. (2006)
Novel iron-specific fluorescent probes
Bioorganic & Medicinal Chemistry Letters, 15, 3450-3452.
Diggle, S P, Matthijs, S, Wright, VJ, Fletcher, MP, Chhabra, SR, Lamont, IIL,
Kong, X, Hider, RC, Cornelis, P, Camara, M, and Williams, P. (2006)
The Pseudomonoas aeruginosa 4-Quinolone Signal Molecules HHQ and PQS
Play Multifunctional Roles in Quorum Sensing and Iron Entrapment.
Chemistry & Biology, 14, 1-10
2006
2006
2006
2006
2006
2006
2007
2007
2007
Merkofer, M, Kissner, R, Hider RC, Brunk, U T, and Koppenol, W H. (2006)
Fenton chemistry and iron chelation under physiologically relevant conditions:
electrochemistry and kinetics
Chemical Research in Toxicology, 10, 1263-1269
Soumyanath, A, Venkatasamy, R, Joshi, M, Faas, L, Adejuyigbe, B, Drake, A F,
hider, R C, and Young, AR. (2006)
UV Irradiation Affects Melanoctye Stimulatory Activity and Protein Binding of
Piperine.
Photochemistry and Photobiology, 82, 1541-1548.
Lin, Zhixiu, Liao, Y, Venkatasamy, R, Hider, RC, and Soumyanath, A. (2006)
Amides from Piper nigrum L. with dissimilar effects on melanocyte
proliferation in-vitro.
Journal of Pharmacy and Pharmacology, 59, 529-536.
Zhou, T, Neubert, H, Liu, DY, Ma, YM, Kong, XL, Luo, W, Sykes, M, and Hider
RC. (2006)
Iron Binding Dendrimers: A Novel Approach for the Treatment of
Haemochromatosis
J. Med. Chem. 49, 4171-4182.,
Lee, D-H, Liu, DY, Jacobs, DR, Shin, HR, Song, K, Lee, I-K, Kim, B, Hider RC.
(2006)
Common Presence of Non-Transferrin Bound Iron Among Patients with Type
2 Diabetes
Diabetes Care, 29, 5
Ren, Y, Houghton, P and Hider RC. (2006)
Relevant activities of extracts and constituents of animals used in traditional
Chinese medicine for central nervous system effects associated with
Alzheimer’s disease
Journal of Pharmacy & Pharmacology, 58, 989-996.
Molina-Holgado, F, Hider, R C, Gaeta, A, Williams, R, Francis, P. (2007)
Metals ions and neurodegeneration
Biometals 20, 639-654
Stephen P Diggle, Sandra Matthijs, Victoria J Wright, Matthew P Fletcher, Siri Ram
Chhabra, Iain L Lamont, Xiaole Kong, Robert C Hider, Pierre Cornelis, Miguel
Camara, and Paul Williams.
The Pseudomonoas aeruginosa 4-Quionolone Signal Molecules HHQ and PQS
Play Multifunctional Roles in Quorum Sensing and Iron Entrapment
Chemistry & Biology, 14, 1-10
Xiaole Kong, Tao Zhou, Zudong Liu, Robert C Hider
pH Indicator Titration: A Novel Fast pka Determination Method
Journal of Pharmaceutical Sciences, 96, 2777-2783
2007
2007
2007
2007
2007
2007
2008
2008
2008
2008
Zhixiu Lin, Yonghong Liao, Radhakrishnan Venkatasamy, Robert C Hider, and
Amala Soumyanath.
Amides from Piper nigrum L. with dissimilar effects on melanocyte
proliferation in-vitro
Journal of Pharmacy & Pharmacology, 59, 529-536
Yongmin Ma, Zudong Liu, Robert Hider, Frank Petrat.
Determination of the Labile Iron Pool of Human Lymphocytes using the
Fluorescent Probe, CP655
Anal. Chem. Insights 2, 61-67
Brandon John Reeder, Robert C Hider, Michael T Wilson
Iron chelators can protect against oxidative stress through ferryl heme
reduction
Free Radical Biology & Medicine, 44, 264-273
Lofollah S Dehkordi, Zu D Liu, Robert Charles Hider
Basic 3-Hydorxypyridin-4-ones: Potential Antimalarial Agents
European Journal of Medicinal Chemistry, In Press
Reem Kayyali, Patricia Evans, Hicham Khodr, Hendrik Neubert, Lakshmi D
Devanur, Robert C Hider
Fenton activity of iron(III) in the presence of deferiprone.
J Pharm Sci, In Press
Brandon Jon Reeder, Francesca Cutruzzola, Maria Giulia Bigotti, Robert C Hider,
Michael T Wilson
Tyrosine as a redox active center in electron transfer to ferryl heme in globins
Free Radical Biology & Medicine, 44, 274-283
Robert Evans, Roozina Rafique, Adel Zarea, Chiara Rapisarda, Richard Cammack,
Pat Evans, John Porter, Robert Hider
Nature of non-transferrin-bound iron:studies on iron citrate complexes and
thalassaemic sera
J Biol. Inorg. Chem 13, 57-74
Francisco Molina-Holgado, Alessandra Gaeta, Paul Francis, Robert Williams,
Robert Hider
Neuroprotective actions of deferiprone in cultured cortical neurons and SHSY-%Y
cells
J. Neurochem. In Press
Bansal SS, Halket JM, Fusova J, Bomford A, Simpson RJ, Vasavda N, Thein
SL,Hider RC. Quantification of hepcidin using matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass
Spectrom.;23(11):1531-1542.
Silva AM, Kong X, Hider RC. Determination of the pKa value of the hydroxyl
group in the alpha-hydroxycarboxylates citrate, malate and lactate by 13C
NMR:implications for metal coordination in biological systems. Biometals.
PubMed PMID: 19288211.
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008
2009
2009
2009
Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S. Iron chelation as a
potential therapy for neurodegenerative disease. Biochem Soc Trans.
36(Pt 6):1304-8. Review. PubMed PMID: 19021545.
Fakih S, Podinovskaia M, Kong X, Collins HL, Schaible UE, Hider RC. Targeting
the lysosome: fluorescent iron(III) chelators to selectively monitor
endosomal/lysosomal labile iron pools. J Med Chem. 14;51(15):4539-52.
Zhou T, Kong XL, Liu ZD, Liu DY, Hider RC. Synthesis and iron(III)-chelating
properties of novel 3-hydroxypyridin-4-one hexadentate ligand-containing
copolymers. Biomacromolecules. 9(5):1372-80.
Molina-Holgado F, Gaeta A, Francis PT, Williams RJ, Hider RC. Neuroprotective
actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J
Neurochem. PubMed PMID: 18331585.
Kong X, Neubert H, Zhou T, Liu ZD, Hider RC. MALDI mass spectrometric
determination of dendritic iron chelation stoichiometries and conditional
affinity constants. J Mass Spectrom. ;43(5):617-22.
Faas L, Venkatasamy R, Hider RC, Young AR, Soumyanath A. In vivo evaluation
of piperine and synthetic analogues as potential treatments for vitiligo using a
sparsely pigmented mouse model. Br J Dermatol. 158(5):941-50.
Hutchinson C, Conway RE, Bomford A, Hider RC, Powell JJ, Geissler CA.
Post-prandial iron absorption in humans: comparison between HFE genotypes
and
iron deficiency anaemia. Clin Nutr. ;27(2):258-63.
Reeder BJ, Cutruzzola F, Bigotti MG, Hider RC, Wilson MT. Tyrosine as a
redox-active center in electron transfer to ferryl heme in globins. Free Radic
Biol Med. 44(3):274-83.
Devanur LD, Evans RW, Evans PJ, Hider RC. Chelator-facilitated removal of
iron from transferrin: relevance to combined chelation therapy. Biochem J.
15;409(2):439-47.
Evans RW, Rafique R, Zarea A, Rapisarda C, Cammack R, Evans PJ, Porter JB,
Hider RC. Nature of non-transferrin-bound iron: studies on iron citrate
complexes and thalassemic sera. J Biol Inorg Chem. 13(1):57-74.
Devanur LD, Neubert H, Hider RC. The fenton activity of iron(III) in the
presence of deferiprone. J Pharm Sci. ;97(4):1454-67.
Bansal SS, Halket JM, Bomford A, Simpson RJ, Vasavda N, Thein SL, Hider RC.
Quantitation of hepcidin in human urine by liquid chromatography-mass
spectrometry. Anal Biochem. 15;384(2):245-53.
Fakih S, Podinovskaia M, Kong X, Schaible UE, Collins HL, Hider RC.
Monitoring intracellular labile iron pools: A novel fluorescent iron(III) sensor
as apotential non-invasive diagnosis tool. J Pharm Sci. 98(6):2212-26.
Laftah AH, Latunde-Dada GO, Fakih S, Hider RC, Simpson RJ, McKie AT. Haem
and folate transport by proton-coupled folate transporter/haem carrier protein
1 (SLC46A1). Br J Nutr.;101(8):1150-6.
2009
2009
2009
2009
2009
2009
2010
2010
2010
2010
2010
2010
2010
Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC,
Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T,
Hendriks JC, Swinkels DW. Results of the first international round robin for the
quantification of urinary and plasma hepcidin assays: need for
standardization.Haematologica.;94(12):1748-52.
Ma YM, Hider RC. The selective quantification of iron by hexadentate
fluorescent probes. Bioorg Med Chem. 2009;17(23):8093-101.
Kerkweg U, Pamp K, Fieker J, Petrat F, Hider RC, de Groot H. Release of
redox-active iron by muscle crush trauma: no liberation into the circulation.
Shock. 2010;33(5):513-8.
Silva AM, Kong X, Parkin MC, Cammack R, Hider RC. Iron(III) citrate
speciation in aqueous solution. Dalton Trans. 2009;(40):8616-25.
Silva AM, Hider RC. Influence of non-enzymatic post-translation modifications
on the ability of human serum albumin to bind iron. Implications for
non-transferrin-bound
iron
speciation.
Biochim
Biophys
Acta.
2009;1794(10):1449-58.
Madlova M, Jones SA, Zwerschke I, Ma Y, Hider RC, Forbes B. Poly(vinylalcohol)
nanoparticle stability in biological media and uptake in respiratory epithelial
cell layers in vitro. Eur J Pharm Biopharm. 2009;72(2):437-43.
Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the
measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc
Nephrol. 2010 ;5(9):1681
Hider RC, Silva AM, Podinovskaia M, Ma Y. Monitoring the efficiency of iron
chelation therapy: the potential of nontransferrin-bound iron. Ann N Y Acad
Sci. 2010 ;1202:94-9.
Staff K, Brown MB, Hider RC, Kong XL, Friden P, Jones SA. Recovering Ga(III)
from coordination complexes using pyridine 2,6-dicarboxylic acid chelation ion
chromatography. Biomed Chromatogr. 2010;24(9):1015-22.
Roy S, Preston JE, Hider RC, Ma YM. Glucosylated deferiprone and its brain
uptake: implications for developing glucosylated hydroxypyridinone analogues
intended to cross the blood-brain barrier. J Med Chem. 2010;53(15):5886-9.
Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, Rose S, Jairaj M,
Tayarani-Binazir KA, Syme A. Design, synthesis and biological evaluation of
L-dopa amide derivatives as potential prodrugs for the treatment of
Parkinson's disease. Eur J Med Chem. 2010;45(9):4035-42.
Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the
shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by
deferiprone. Transl Res. 2010;156(2):55-67.
Lan Y, Langlet-Bertin B, Abbate V, Vermeer LS, Kong X, Sullivan KE, Leborgne
C, Scherman D, Hider RC, Drake AF, Bansal SS, Kichler A, Mason AJ.
Incorporation of 2,3-diaminopropionic acid into linear cationic amphipathic
peptides produces pH-sensitive vectors. Chembiochem. 2010;11(9):1266-72.
2010
2010
2010
2010
2010
2010
2011
2011
2011
2011
2011
2011
2011
Piyamongkol S, Ma YM, Kong XL, Liu ZD, Aytemir MD, van der Helm D, Hider
RC. Amido-3-hydroxypyridin-4-ones as iron(III) ligands. Chemistry.
2010;16(21):6374-81.
Bansal SS, Abbate V, Bomford A, Halket JM, Macdougall IC, Thein SL, Hider RC.
Quantitation of hepcidin in serum using ultra-high-pressure liquid
chromatography and a linear ion trap mass spectrometer. Rapid Commun Mass
Spectrom. 2010;24(9):1251-9.
Hider RC, Kong X. Chemistry and biology of siderophores. Nat Prod Rep.
2010;27(5):637-57.
Nunes A, Podinovskaia M, Leite A, Gameiro P, Zhou T, Ma Y, Kong X, Schaible
UE, Hider RC, Rangel M. Fluorescent 3-hydroxy-4-pyridinone hexadentate iron
chelators: intracellular distribution and the relevance to antimycobacterial
properties. J Biol Inorg Chem. 2010;15(6):861-77.
Hider RC. Charge states of deferasirox-ferric iron complexes. Am J Kidney
Dis. 2010;55(3):614-5.
Fernandes SS, Nunes A, Gomes AR, de Castro B, Hider RC, Rangel M, Appelberg
R, Gomes MS. Identification of a new hexadentate iron chelator capable of
restricting the intramacrophagic growth of Mycobacterium avium. Microbes
Infect. 2010;12(4):287-94.
Qiu DH, Huang ZL, Zhou T, Shen C, Hider RC. In vitro inhibition of bacterial
growth by iron chelators. FEMS Microbiol Lett. 2011;314(2):107-11. doi:
10.1111/j.1574-6968.2010.02153.x.
Gaeta A, Molina-Holgado F, Kong XL, Salvage S, Fakih S, Francis PT, Williams
RJ, Hider RC. Synthesis, physical-chemical characterisation and biological
evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with
the potential for treating Alzheimer's disease. Bioorg Med Chem. 2011
1;19(3):1285-97.
Staff K, Brown MB, Chilcott RP, Hider RC, Jones SA, Kong XL. Ga(III)
complexes--the effect of metal coordination on potential systemic absorption
after topical exposure. Toxicol Lett. 2011;202(3):155-60.
Hider RC, Roy S, Ma YM, Le Kong X, Preston J. The potential application of
iron chelators for the treatment of neurodegenerative diseases. Metallomics.
2011;3(3):239-49.
Yoshimura E, Kohdr H, Mori S, Hider RC. The binding of aluminum to mugineic
acid and related compounds as studied by potentiometric titration. Biometals.
2011 [Epub ahead of print] PubMed PMID: 21350950.
Baek JH, Reiter CE, Manalo DJ, Buehler PW, Hider RC, Alayash AI. Induction of
hypoxia inducible factor (HIF-1α) in rat kidneys by iron chelation with the
hydroxypyridinone, CP94. Biochim Biophys Acta. 2011 ;1809(4-6):262-8.
Berry DJ, Ma Y, Ballinger JR, Tavaré R, Koers A, Sunassee K, Zhou T, Nawaz S,
Mullen GE, Hider RC, Blower PJ. Efficient bifunctional gallium-68 chelators for
positron emission tomography: tris(hydroxypyridinone) ligands. Chem Commun
(Camb). 2011
2011
Zhou T, Winkelmann G, Dai ZY, Hider RC. Design of clinically useful
macromolecular iron chelators. J Pharm Pharmacol. 2011